- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 680KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 368KB)
Nivolumab – July 2023
Nivolumab (non-small cell lung cancer): Injection concentrate for I.V. infusion 40 mg in 4 mL vial, Injection concentrate for I.V. infusion 100 mg in 10 mL vial; Opdivo®
Last updated
27 October 2023